As part of our ongoing aim to bring you reports of interesting new studies, we have added a review of a study titled: Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): A multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Independent expert commentary is provided by Professor Miles Prince, an Australian haematologist and Professor of Medicine at both Melbourne and Monash Universities.
Please login below to download this issue (PDF)